Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus irinotecan as second-line therapy for metastatic colorectal cancer
2006-006363-24Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and irinotecan in metastatic colorectal adenocarcinoma (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective response rate. Started Jan 2007; status: completed.
02
Drugs
panitumumabirinotecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-006363-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006363-24.